NASDAQ:RVPH

Reviva Pharmaceuticals Q2 2026 Earnings Results & Report

Reviva Pharmaceuticals logo
$0.34 +0.05 (+17.96%)
As of 11/20/2026 03:57 PM Eastern

Reviva Pharmaceuticals beat analyst earnings expectations in its Q2 2026 results, released August 13, 2026. The company reported EPS of -$0.19 versus the -$0.3850 consensus estimate.

Earnings Announcement Details

Quarter
Q2 2026
Report Date
Time
After Market Closes
Conference Call Date
Conference Call
4:00 PM ET

Reviva Pharmaceuticals EPS Results

Actual EPS
-$0.19
Consensus EPS
-$0.3850
Beat/Miss
Beat by +$0.1950
One Year Ago EPS
N/A
EPS Beat Rate
7 of last 8 quarters

Reviva Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Reviva Pharmaceuticals Q2 2026 Earnings FAQ

Reviva Pharmaceuticals (NASDAQ:RVPH) reported earnings of -$0.19 per share for Q2 2026, beating the consensus estimate of -$0.3850. The report was announced on Thursday, August 13, 2026.

Reviva Pharmaceuticals Earnings Headlines

RVPH: FDA Feedback on New Formulation Imminent
Worse than socialism
Donald Trump and Bernie Sanders rarely agree on anything, yet both are steering the country toward the same economic system, according to veteran analyst Porter Stansberry. The government has already taken stakes in companies like Intel, Lithium Americas, and MP Materials, while political rhetoric on both sides points toward deeper centralization. Stansberry has spent months investigating what this bipartisan shift could mean for investors navigating the months ahead.tc pixel
See More Reviva Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Reviva Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Reviva Pharmaceuticals and other key companies, straight to your email.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals (NASDAQ:RVPH) is a clinical-stage biopharmaceutical company focused on developing treatments for disorders involving the central nervous system, respiratory system and inflammation. The company is headquartered in Cupertino, California, and was founded in 2006.

Its lead drug candidate, brilaroxazine (also known as RP5063), is an investigational compound being developed for schizophrenia and other neuropsychiatric conditions. Reviva has also described potential applications for the candidate in respiratory and other disorders. Brilaroxazine is not an approved or marketed medicine.

Reviva’s work centers on research and clinical development of its drug candidates; the company does not currently offer commercial pharmaceutical products.

View Reviva Pharmaceuticals Profile